Repository logo
 
Publication

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

2017-09Journal article Open access
Simple item page
dc.contributor.authorAfonso, Joana
dc.contributor.authorde Sousa, Helena Tavares
dc.contributor.authorRosa, Isadora
dc.contributor.authorCarvalho, João
dc.contributor.authorDias, Claudia Camila
dc.contributor.authorMagro, Fernando
dc.date.accessioned2018-12-07T14:58:12Z
dc.date.available2018-12-07T14:58:12Z
dc.date.issued2017-09
dc.description.abstractBackground: The commercialization of CT-P13, an infliximab (IFX) biosimilar, has the potential to decrease health-related costs and enhance access to biological therapies. This study aimed to address the accuracy and inter-assay agreement of the CT-P13 quantification using four different assays initially developed to assess IFX. Methods: The four different methods, one in-house method and three commercially available kits, were used to quantify exogenously-spiked samples and the sera from 185 inflammatory bowel disease (IBD) patients on CT-P13 therapy. Results: The quantification of the spiked samples unveiled a consistent and accurate behaviour of three of the tested methods, with average percentage recoveries of 90%, 102% and 109%. Results from the clinical samples demonstrated that these three assays were also highly correlated, both concerning Spearman's rank coefficients (range 0.890-0.947) and intraclass correlation coefficients (range 0.907-0.935). There were a few systematic deviations among them, but their impact in the clinical stratification of the patients using different cut-offs was minimal, particularly when these cut-offs were in the 3-4 mu g/ml range, for which the strength of agreement (as assessed by the Kappa statistics that ranged from 0.732 to 0.902) was substantial to almost perfect. Conclusions: Our results indicate that three of the tested IFX quantification methods can be used to accurately quantify CT-P13 without any adjustments.
dc.description.sponsorshipPortuguese IBD Group (GEDII, Grupo de Estudo da Doenca Inflamatoria Intestinal)
dc.description.sponsorshipPortuguese IBD Group (GEDII, Grupo de Estudo da Doença Inflamatória Intestinal)
dc.identifier.doi10.1177/1756283X17722915
dc.identifier.issn1756-283X
dc.identifier.issn1756-2848
dc.identifier.urihttp://hdl.handle.net/10400.1/11906
dc.language.isoeng
dc.peerreviewedyes
dc.publisherSage Publications Ltd
dc.subjectInflammatory bowel disease
dc.subjectAnti infliximab antibodies
dc.subjectCrohns disease
dc.subjectAnkylosing spondylitis
dc.subjectInnovator infliximab
dc.subjectUlcerative colitis
dc.subjectSerum infliximab
dc.subjectParallel group
dc.subjectDouble blind
dc.subjectElisa kits
dc.titleTherapeutic drug monitoring of CT-P13: a comparison of four different immunoassays
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage671
oaire.citation.issue9
oaire.citation.startPage661
oaire.citation.titleTherapeutic Advances in Gastroenterology
oaire.citation.volume10
rcaap.rightsopenAccess
rcaap.typearticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Therapeutic drug monitoring of CT-P13, a comparison of four different immunoassays.pdf
Size:
142.7 KB
Format:
Adobe Portable Document Format
Download

Collections

FCB2-Artigos (em revistas ou actas indexadas)